...ectodermal dysplasia (XLHED) in which InformedDNA may identify individuals that may benefit from treatment with Edimer’s...
...in the U.S. and EU and Fast Track designation in the U.S. for the indication. Edimer Pharmaceuticals Inc....

...December 2012 and in the $18 million series B round for fellow rare disease company Edimer...

...a $75 million series B round for Ultragenyx Pharmaceutical Inc. in December 2012 and in Edimer Pharmaceuticals Inc....
...inhibitors, which can reestablish the immune system's ability to detect tumors. Companies and Institutions Mentioned Edimer Pharmaceuticals Inc....

...in the U.S. and EU and Fast Track designation in the U.S. for the indication. Edimer Pharmaceuticals Inc....

...existing investors Third Rock Ventures and VI Partners. NEA's David Mott will join Edimer's board. Edimer's...

...Jeff Behrens as CEO. He was previously senior director of business development and operations at Edimer Pharmaceuticals Inc....

...Jeff Behrens as CEO. He was previously senior director of business development and operations at Edimer Pharmaceuticals Inc....

...Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of...
...administration of EDI200 in the mouse model permanently corrected the XLHED phenotype. Kirby noted that Edimer...
...programs and opted to lead Edimer's $22 million series A round in 2009. Kirby said Edimer...